Johnson & Johnson (JNJ) reported Q2 FY 2017 earnings of $1.83 per share (versus $1.74 in Q2 FY 2016), beating analysts' consensus estimate of $1.79.

The company's quarterly revenues amounted to $18.839 bln (+1.9% y/y), generally in-line with analysts' consensus estimate of $18.942 bln.

The company also issued upside guidance for FY 2017, raising EPS forecast to $7.12-7.22 from $7.00-7.15, (versus analysts' consensus estimate of $7.11) and revenues expectations to $75.8-76.1 bln from $75.4-76.1 bln (versus analysts' consensus estimate of $75.65 bln).

JNJ rose to $133.51 (+1.03%) in pre-market trading.